一项基于RNA干扰的筛选揭示了PLK1、CDK1和NDC80是恶性胸膜间皮瘤潜在的治疗靶点。
An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma.
作者信息
Linton A, Cheng Y Y, Griggs K, Schedlich L, Kirschner M B, Gattani S, Srikaran S, Chuan-Hao Kao S, McCaughan B C, Klebe S, van Zandwijk N, Reid G
机构信息
Asbestos Diseases Research Institute (ADRI), University of Sydney, Concord, NSW 2139, Australia.
Department of Anatomical Pathology, Flinders Medical Centre, Bedford, SA, Australia.
出版信息
Br J Cancer. 2018 Mar 20;118(6):e13. doi: 10.1038/bjc.2018.3. Epub 2018 Feb 13.
Abstract
This corrects the article DOI: 10.1038/bjc.2017.85.
摘要
本文更正了文章的数字对象标识符
10.1038/bjc.2017.85 。
相似文献
1
An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma.一项基于RNA干扰的筛选揭示了PLK1、CDK1和NDC80是恶性胸膜间皮瘤潜在的治疗靶点。
Br J Cancer. 2018 Mar 20;118(6):e13. doi: 10.1038/bjc.2018.3. Epub 2018 Feb 13.
2
Comprehensive analysis of differentially expressed genes associated with PLK1 in bladder cancer.膀胱癌中与 PLK1 相关的差异表达基因的综合分析。
BMC Cancer. 2017 Dec 16;17(1):861. doi: 10.1186/s12885-017-3884-2.
3
Sequential phosphorylation of Nedd1 by Cdk1 and Plk1 is required for targeting of the gammaTuRC to the centrosome.Cdk1和Plk1对Nedd1进行顺序磷酸化是γ微管蛋白环形复合物（γTuRC）定位于中心体所必需的。
J Cell Sci. 2009 Jul 1;122(Pt 13):2240-51. doi: 10.1242/jcs.042747. Epub 2009 Jun 9.
4
Selective activation of insulin receptor substrate-1 and -2 in pleural mesothelioma cells: association with distinct malignant phenotypes.胰岛素受体底物-1和-2在胸膜间皮瘤细胞中的选择性激活：与不同恶性表型的关联
Cancer Res. 2004 Oct 15;64(20):7479-85. doi: 10.1158/0008-5472.CAN-04-1898.
5
Pleural-based mesothelioma in immune competent rats: a model to study adenoviral gene transfer.免疫功能正常大鼠的胸膜间皮瘤：一种研究腺病毒基因转移的模型
Ann Thorac Surg. 1995 Sep;60(3):593-7; discussion 597-8. doi: 10.1016/0003-4975(95)00507-H.
6
Clinical course of human epithelial-type malignant pleural mesothelioma replicated in an orthotopic-transplant nude mouse model.人上皮型恶性胸膜间皮瘤的临床病程在原位移植裸鼠模型中的复制情况。
Anticancer Res. 1996 Mar-Apr;16(2):633-9.
7
Advances in the biology of malignant pleural mesothelioma.恶性胸膜间皮瘤的生物学进展。
Cancer Treat Rev. 2011 Nov;37(7):543-58. doi: 10.1016/j.ctrv.2011.01.001. Epub 2011 Feb 1.
8
Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma.顺铂联合西罗莫司治疗增强人胸膜间皮瘤细胞死亡。
J Thorac Cardiovasc Surg. 2010 May;139(5):1233-40. doi: 10.1016/j.jtcvs.2009.06.027. Epub 2009 Oct 22.
9
Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines.顺铂和培美曲塞在恶性胸膜间皮瘤细胞系中的相互作用和交叉耐药性。
Oncol Rep. 2012 Jul;28(1):33-40. doi: 10.3892/or.2012.1799. Epub 2012 May 4.
10
[Malignant pleural mesothelioma with an unusual radiologic manifestation].[具有不寻常放射学表现的恶性胸膜间皮瘤]
An Med Interna. 1999 Jul;16(7):354-6.
引用本文的文献
1
as a potential pan-cancer diagnostic, prognostic, and immunological biomarker.作为一种潜在的泛癌诊断、预后和免疫生物标志物。
Transl Cancer Res. 2024 Mar 31;13(3):1533-1553. doi: 10.21037/tcr-23-2016. Epub 2024 Mar 27.
2
Development of an interfering peptide M1-20 with potent anti-cancer effects by targeting FOXM1.靶向 FOXM1 的干扰肽 M1-20 的抗肿瘤作用研究进展。
Cell Death Dis. 2023 Aug 19;14(8):533. doi: 10.1038/s41419-023-06056-9.
3
shRNA targeting PLK1 inhibits the proliferation and invasion of nasopharyngeal carcinoma cells.靶向PLK1的短发夹RNA抑制鼻咽癌细胞的增殖和侵袭。
Transl Cancer Res. 2020 Sep;9(9):5350-5359. doi: 10.21037/tcr-20-811.
4
Identification of as a candidate marker in cutaneous squamous cell carcinoma by integrated bioinformatics analysis.通过综合生物信息学分析鉴定某物质作为皮肤鳞状细胞癌的候选标志物。 （注：原文中“Identification of as a candidate marker”这里少了具体要鉴定的对象，我按照常规翻译补上了“某物质”，你可根据实际情况修改。）
Transl Cancer Res. 2021 Jan;10(1):469-478. doi: 10.21037/tcr-20-2945.
5
Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC).细胞周期蛋白依赖性激酶-1（CDK-1）抑制作为一种针对胰腺导管腺癌（PDAC）的新型治疗策略。
Cancers (Basel). 2021 Aug 30;13(17):4389. doi: 10.3390/cancers13174389.
Zotero 插件